NYSE:DHRLife Sciences
How Evercore’s Target Cut And Masimo Deal Debate At Danaher (DHR) Has Changed Its Investment Story
In early April 2026, Evercore ISI reaffirmed its positive view on Danaher while trimming its price target, as investors focused on the company’s upcoming Q1 2026 earnings and ongoing integration of the Masimo acquisition announced in February.
Beyond analyst opinions, Danaher’s recent trading has been shaped by stronger sentiment across medical technology and life science tools, with sector momentum amplifying attention on its diagnostics expansion through Masimo’s sensor and AI-enabled...